The investigation into Ursula von der Leyen, the president of the European Commission, for alleged irregularities in the purchase of Pfizer vaccines during the covid-19 pandemic has been on hold until December 6. The delay coincides with the European elections, providing her with protection at a crucial time as she is in the midst of an electoral campaign as a candidate for the European People’s Party.
The case focuses on the conditions and transparency of the massive purchase of covid vaccines by the European Commission and Member States, involving a large expenditure of funds. Von der Leyen has faced criticism for her refusal to disclose SMS exchanges with Pfizer’s CEO related to vaccine purchases, prompting the EU Ombudsman to question the Commission’s transparency.
The investigation began in October 2022 with the European Public Prosecutor’s Office (EPPO), but it has kept silent about any potential role played by Von der Leyen. Last year, a similar lawsuit was filed in Belgium, and now EPPO has taken over the investigation and decision-making process.
A hearing was held where both Von der Leyen and Pfizer’s CEO were summoned, but only their lawyers attended. The case has been suspended until December 6, providing a shield to Von der Leyen amidst ongoing election campaigns and selecting new European commissioners. The delay in the case means that no legal action will be taken during upcoming European elections and subsequent processes forming a new European Commission.
